AR094466A1 - Proceso para la obtención de un derivado de fluorlactona - Google Patents
Proceso para la obtención de un derivado de fluorlactonaInfo
- Publication number
- AR094466A1 AR094466A1 ARP140100100A ARP140100100A AR094466A1 AR 094466 A1 AR094466 A1 AR 094466A1 AR P140100100 A ARP140100100 A AR P140100100A AR P140100100 A ARP140100100 A AR P140100100A AR 094466 A1 AR094466 A1 AR 094466A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- derivative
- fluorlactone
- obtaining
- aldol
- Prior art date
Links
- HSJKGGMUJITCBW-UHFFFAOYSA-N 3-hydroxybutanal Chemical compound CC(O)CC=O HSJKGGMUJITCBW-UHFFFAOYSA-N 0.000 abstract 6
- 241000711549 Hepacivirus C Species 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 abstract 1
- 150000001299 aldehydes Chemical class 0.000 abstract 1
- 230000003301 hydrolyzing effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/26—Oxygen atoms attached in position 2 with hetero atoms or acyl radicals directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Furan Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Inhibidores de la polimerasa NS5B del virus de la hepatitis C (HCV). Reivindicación 1: Proceso para la obtención de un derivado de fluorlactona de la fórmula (1) que consta de los pasos siguientes: a) hacer reaccionar el aldehído de la fórmula (2) con un derivado fluorpropionato de la fórmula (3) en la que A se elige entre los restos quirales de fórmula (A1), (A2) y (A3) y Ph significa fenilo, para formar un aducto aldol de la fórmula (4) en la que A tiene el significado definido anteriormente; y b) someter a hidrólisis el aducto aldol de la fórmula (4) para generar el derivado de fluorlactona de la fórmula (1). Reivindicación 20: Aducto aldol de la fórmula (4) en la que A se elige entre los restos quirales de fórmula (A1), (A2) y (A3) en los que Ph significa fenilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013070413 | 2013-01-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR094466A1 true AR094466A1 (es) | 2015-08-05 |
Family
ID=49989697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140100100A AR094466A1 (es) | 2013-01-14 | 2014-01-10 | Proceso para la obtención de un derivado de fluorlactona |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9624183B2 (es) |
| EP (1) | EP2943475B1 (es) |
| JP (1) | JP6317367B2 (es) |
| KR (2) | KR102187280B1 (es) |
| AR (1) | AR094466A1 (es) |
| BR (1) | BR112015016647A2 (es) |
| CA (1) | CA2896253C (es) |
| ES (1) | ES2655851T3 (es) |
| HK (2) | HK1215020A1 (es) |
| IL (1) | IL239697A (es) |
| MX (1) | MX2015008661A (es) |
| PT (1) | PT2943475T (es) |
| RU (1) | RU2656600C2 (es) |
| SG (1) | SG11201505455VA (es) |
| WO (1) | WO2014108525A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2726998T3 (es) | 2003-05-30 | 2019-10-11 | Gilead Pharmasset Llc | Análogos de nucleósidos fluorados modificados |
| AR094466A1 (es) | 2013-01-14 | 2015-08-05 | Hoffmann La Roche | Proceso para la obtención de un derivado de fluorlactona |
| CN105111169A (zh) * | 2015-07-08 | 2015-12-02 | 重庆沃肯精细化工有限公司 | 一种索菲布韦关键中间体的简便制备方法 |
| US10611739B2 (en) | 2016-08-16 | 2020-04-07 | Pharmaresources (Shanghai) Co., Ltd. | Process for preparation of lactone derivatives and intermediates thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ568909A (en) | 2005-12-09 | 2011-10-28 | Hoffmann La Roche | Antiviral 4-fluoro-4-methyl nucleoside prodrugs |
| WO2008074693A2 (en) * | 2006-12-18 | 2008-06-26 | F. Hoffmann-La Roche Ag | Process for preparing 3,5-di-omicron-acyl-2-fluoro-2-c-methyl-d-ribono-gamma-lactone |
| WO2008090046A1 (en) * | 2007-01-23 | 2008-07-31 | F. Hoffmann-La Roche Ag | Alternate process for preparing 3,5-di-omicron-acyl-2-fluoro-2-c-methyl-d-ribono-gamma-lactone |
| AR094466A1 (es) | 2013-01-14 | 2015-08-05 | Hoffmann La Roche | Proceso para la obtención de un derivado de fluorlactona |
-
2014
- 2014-01-10 AR ARP140100100A patent/AR094466A1/es unknown
- 2014-01-13 RU RU2015130337A patent/RU2656600C2/ru not_active IP Right Cessation
- 2014-01-13 SG SG11201505455VA patent/SG11201505455VA/en unknown
- 2014-01-13 EP EP14700590.4A patent/EP2943475B1/en active Active
- 2014-01-13 BR BR112015016647A patent/BR112015016647A2/pt not_active Application Discontinuation
- 2014-01-13 JP JP2015552063A patent/JP6317367B2/ja active Active
- 2014-01-13 ES ES14700590.4T patent/ES2655851T3/es active Active
- 2014-01-13 WO PCT/EP2014/050439 patent/WO2014108525A1/en active Application Filing
- 2014-01-13 PT PT147005904T patent/PT2943475T/pt unknown
- 2014-01-13 MX MX2015008661A patent/MX2015008661A/es unknown
- 2014-01-13 KR KR1020157021634A patent/KR102187280B1/ko active IP Right Grant
- 2014-01-13 CA CA2896253A patent/CA2896253C/en active Active
- 2014-01-13 KR KR1020207034457A patent/KR20200138424A/ko not_active Application Discontinuation
-
2015
- 2015-06-29 IL IL239697A patent/IL239697A/en not_active IP Right Cessation
- 2015-07-14 US US14/798,879 patent/US9624183B2/en active Active
-
2016
- 2016-03-14 HK HK16102911.4A patent/HK1215020A1/zh unknown
- 2016-05-17 HK HK16105636.1A patent/HK1219094A1/zh unknown
-
2017
- 2017-03-09 US US15/454,561 patent/US9845299B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20150315165A1 (en) | 2015-11-05 |
| EP2943475B1 (en) | 2017-10-25 |
| RU2015130337A (ru) | 2017-02-20 |
| ES2655851T3 (es) | 2018-02-21 |
| SG11201505455VA (en) | 2015-08-28 |
| IL239697A (en) | 2017-12-31 |
| HK1215020A1 (zh) | 2016-08-12 |
| KR102187280B1 (ko) | 2020-12-07 |
| MX2015008661A (es) | 2015-10-05 |
| HK1219094A1 (zh) | 2017-03-24 |
| PT2943475T (pt) | 2018-01-17 |
| WO2014108525A1 (en) | 2014-07-17 |
| US9845299B2 (en) | 2017-12-19 |
| IL239697A0 (en) | 2015-08-31 |
| US20170183317A1 (en) | 2017-06-29 |
| EP2943475A1 (en) | 2015-11-18 |
| US9624183B2 (en) | 2017-04-18 |
| JP6317367B2 (ja) | 2018-04-25 |
| CA2896253A1 (en) | 2014-07-17 |
| KR20200138424A (ko) | 2020-12-09 |
| BR112015016647A2 (pt) | 2017-07-11 |
| RU2656600C2 (ru) | 2018-06-06 |
| CA2896253C (en) | 2021-01-12 |
| KR20150104205A (ko) | 2015-09-14 |
| JP2016508154A (ja) | 2016-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123164T1 (el) | Διεργασια για τη συνθεση ενος αναστολεα ινδολαμινης 2,3-διοξυγενασης | |
| AR110381A2 (es) | Inhibidores biarilo de tirosina cinasa de bruton | |
| EA201690452A1 (ru) | Ингибиторы полимеразы hcv | |
| CR20160098A (es) | Polimorfo de los inhibidores de la syk | |
| CR20200276A (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamientos de la hepatitis b (divisional exp. 2015-0059) | |
| CO7160104A2 (es) | Inhibidores de virus de hepatitis c | |
| CO6761335A2 (es) | Inhibidores del virus de la hepatitis c | |
| EA201391637A1 (ru) | Ингибиторы вируса гепатита c | |
| AR105494A1 (es) | Método para preparar derivados de ácido 3-(2-anilino-1-ciclohexil-1h-bencimidazol-5-il)propanoico sustituido | |
| EA201790983A1 (ru) | Синтез копанлисиба и его дигидрохлорида | |
| UY34245A (es) | Compuestos antivirales para el tratamiento de la hepatitis c (hcv), y métodos de tratamiento. | |
| CR20160459A (es) | Nuevos derivados de piridina | |
| EA201391717A1 (ru) | Ингибиторы вируса гепатита с | |
| EA201590770A1 (ru) | Ингибиторы вируса гепатита с | |
| AR094466A1 (es) | Proceso para la obtención de un derivado de fluorlactona | |
| UY36221A (es) | Derivados de isoindolinona | |
| EA201690696A1 (ru) | Способ получения адамантанамидов | |
| EA201691983A1 (ru) | Пиридин-2-амиды, пригодные в качестве агонистов cb2 | |
| AR093738A1 (es) | Formas solidas que comprenden inhibidores de ns5a de hcv, sus composiciones y sus usos | |
| CY1121116T1 (el) | Νεα μεθοδος για την συνθεση αγομελατινης | |
| BR112016027455A2 (pt) | moduladores ppar | |
| BR112015015798A2 (pt) | método para a preparação de um composto | |
| AR098879A1 (es) | Síntesis de ent-progesterona y sus productos intermedios | |
| DK3219388T3 (da) | Fremgangsmåde til katalytisk nedbrydning af aldehyd i en forbrændingsudstødningsgas | |
| MX2015014728A (es) | Sintesis de inhibidores de beta secretasa (bace). |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |